– tackling two of the most intensely regulated pathways in one go
Combination products are a fast developing market but a tricky one.
Yet this market is really picking up speed. New technologies enable patient care in ever improving levels. But how do you tackle two of the most intensely regulated pathways in one go?
Join us and learn more about the possibilities and the pitfalls!
Date: 29th September 2021
Time: 10:00 – 11:00
|9:50||Online platform opens for registering participants|
David Munis Zepernick, Head of Business Development and Public Affairs, Medicon Valley Alliance
|10:05||Pharmaceuticals & Medical Devices combined – tackling two of the most intensely regulated pathways in one go|
Satu Päiväläinen, Specialist, Clinical affairs and IVD, Innokas Medical Ltd
|11:00||End of webinar|
|Satu Päiväläinen Ph.D. Biochemistry|
Satu Päiväläinen has an extensive background in science as well as in Pharmaceutical and MedTech industries giving her an exceptional understanding of the core of Health Tech development. In her role as Clinical Development Lead she gained an in-depth understanding of (pre)clinical development, including testing practices and requirements. In MedTech, Satu has worked, amongst others, with biological risk assessment, which is one of the key topics considering development of combination products. Satu has altogether an over 7 years of experience in working with regulatory affairs.
|Organized by||In collaboration with|